Literature DB >> 900926

Cytotoxicity and cell cycle specificity of homoharringtonine.

D M Baaske, P Heinstein.   

Abstract

The plant alkaloid, homoharringtonine, isolated from Cephalotaxus harringtonia is cytotoxic to HeLa, KB, and L cells growing in monolayer cell cultures. This effect appears to be cell-cycle specific. In synchronized KB cells, protein synthesis was preferentially inhibited in the G(1) and G(2) phases (70 and 45% inhibition, respectively) as might be expected for a protein-synthesis inhibitor.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 900926      PMCID： PMC429904          DOI： 10.1128/AAC.12.2.298

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  STUDIES ON SYNCHRONOUS DIVISION OF TISSUE CULTURE CELLS INITIATED BY EXCESS THYMIDINE.

Authors:  D BOOTSMA; L BUDKE; O VOS
Journal:  Exp Cell Res       Date:  1964-01       Impact factor: 3.905

2.  Deoxyriboside control and synchronization of mitosis.

Authors:  N XEROS
Journal:  Nature       Date:  1962-05-19       Impact factor: 49.962

3.  Propagation in a fluid medium of a human epidermoid carcinoma, strain KB.

Authors:  H EAGLE
Journal:  Proc Soc Exp Biol Med       Date:  1955-07

4.  Measurement of cell growth in tissue culture with a phenol reagent (folin-ciocalteau).

Authors:  V I OYAMA; H EAGLE
Journal:  Proc Soc Exp Biol Med       Date:  1956-02

Review 5.  Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer.

Authors:  V T DeVita; R C Young; G P Canellos
Journal:  Cancer       Date:  1975-01       Impact factor: 6.860

6.  Harringtonine, an inhibitor of initiation of protein biosynthesis.

Authors:  M T Huang
Journal:  Mol Pharmacol       Date:  1975-09       Impact factor: 4.436

7.  Deoxyribonucleic acid synthesis in synchronized mammalian KB cells infected with herpes simplex virus.

Authors:  G H Cohen; R K Vaughan; W C Lawrence
Journal:  J Virol       Date:  1971-06       Impact factor: 5.103

8.  Antitumor alkaloids for Cephalataxus harringtonia: structure and activity.

Authors:  R G Powell; D Weisleder; C R Smith
Journal:  J Pharm Sci       Date:  1972-08       Impact factor: 3.534

9.  Structures of harringtonine, isoharringtonine, and homoharringtonine.

Authors:  R G Powell; D Weisleder; C R Smith; W K Rohwedder
Journal:  Tetrahedron Lett       Date:  1970-03       Impact factor: 2.415

10.  LIFE CYCLE ANALYSIS OF MAMMALIAN CELLS. I. A METHOD FOR LOCALIZING METABOLIC EVENTS WITHIN THE LIFE CYCLE, AND ITS APPLICATION TO THE ACTION OF COLCEMIDE AND SUBLETHAL DOSES OF X-IRRADIATION.

Authors:  T T PUCK; J STEFFEN
Journal:  Biophys J       Date:  1963-09       Impact factor: 4.033
View more
  9 in total

Review 1.  Potential of plant-derived natural products in the treatment of leukemia and lymphoma.

Authors:  David M Lucas; Patrick C Still; Lynette Bueno Pérez; Michael R Grever; A Douglas Kinghorn
Journal:  Curr Drug Targets       Date:  2010-07       Impact factor: 3.465

Review 2.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.

Authors:  N Daver; A Vega-Ruiz; H M Kantarjian; Z Estrov; A Ferrajoli; S Kornblau; S Verstovsek; G Garcia-Manero; J E Cortes
Journal:  Eur J Cancer Care (Engl)       Date:  2013-05-23       Impact factor: 2.520

4.  Novel homobarringtonie-containing therapy for the treatment of patients with primary acute myeloid leukemia that are resistant to conventional therapy.

Authors:  Jingsong He; Li Li; Jingjing Zhu; Weiyan Zheng; Wenjun Wu; Yanlong Zheng; Xiujin Ye
Journal:  Oncol Lett       Date:  2017-09-27       Impact factor: 2.967

5.  Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin.

Authors:  H P Hofs; D J Wagener; V De Valk-Bakker; H Van Rennes; D De Vos; W H Doesburg; H C Ottenheijm; W J De Grip
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

6.  Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor.

Authors:  L M Lindqvist; I Vikström; J M Chambers; K McArthur; M Ann Anderson; K J Henley; L Happo; L Cluse; R W Johnstone; A W Roberts; B T Kile; B A Croker; C J Burns; M A Rizzacasa; A Strasser; D C S Huang
Journal:  Cell Death Dis       Date:  2012-10-11       Impact factor: 8.469

7.  Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein.

Authors:  Jiang Cao; Hao Feng; Ning-Ning Ding; Qing-Yun Wu; Chong Chen; Ming-Shan Niu; Wei Chen; Ting-Ting Qiu; Hong-Hu Zhu; Kai-Lin Xu
Journal:  Cancer Med       Date:  2016-10-05       Impact factor: 4.452

8.  MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1.

Authors:  MinRan Zhou; JiPing Zeng; XiaoMing Wang; Qing Guo; Tao Huang; HaiYu Shen; Yue Fu; LiXiang Wang; JiHui Jia; ChunYan Chen
Journal:  J Transl Med       Date:  2013-10-23       Impact factor: 5.531

9.  The Natural Compound Homoharringtonine Presents Broad Antiviral Activity In Vitro and In Vivo.

Authors:  Hui-Jun Dong; Zhao-Hua Wang; Wen Meng; Cui-Cui Li; Yan-Xin Hu; Lei Zhou; Xiao-Jia Wang
Journal:  Viruses       Date:  2018-11-01       Impact factor: 5.048
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.